BURLINGTON, Mass., Sept. 17, 2015 /PRNewswire/ -- Decision Resources Group finds that the majority of German patients receiving an infliximab biosimilar were biologic-naive and would have received Remicade or another biologic if they had not received a biosimilar, according to surveyed German rheumatologists and gastroenterologists. At three months post launch of infliximab biosimilars (Inflectra/Remsima), less than one-quarter of respondents had experienced any pressure from healthcare authorities to switch patients currently treated with Remicade to receive an infliximab biosimilar.

Other key findings from the biosimilars report entitled LaunchTrends: Inflectra/Remsima (Germany):

  • Almost one half of surveyed German gastroenterologists and 37% of rheumatologists consider themselves to be very or extremely familiar with biosimilars, but less than one-third of these physicians are aware that Inflectra and Remsima have been approved for the same indications as Remicade.
  • Over 40% of surveyed rheumatologists and gastroenterologists have prescribed at least one of the biosimilars to one or more of their patients.

Comments from Decision Resources Group Senior Director, Kate Keeping:

  • "So far, it seems that German rheumatologists and gastroenterologists are able to choose when they wish to prescribe biosimilar infliximab. However, it is highly likely that pressure to use an infliximab biosimilar will increase, particularly as more infliximab biosimilars enter the market and we begin to see downward pressure on prices."
  • "Although German physicians typically have a better understanding of biosimilar concepts than physicians from neighboring France, or the United States, survey respondents had a surprisingly poor understanding of how Inflectra/Remsima was tested in clinical trials or what it is approved for, suggesting there is more work to do to improve awareness about biosimilars, even in Germany."

For more information on purchasing this report, please email questions@teamDRG.com.

About Decision Resources Group

Decision Resources Group offers best-in-class, high-value data, analytics and insights products and services to the healthcare industry, delivered by more than 900 employees across 14 global locations. DRG provides the pharmaceutical, biotech, medical device, financial services and payer industries with the tools, insights and advice they need to compete and thrive in an increasingly complex and value-based marketplace. DecisionResourcesGroup.com.

Media contact:
SHIFT Communications
Theresa Masnik

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

Cost-Constrained Payers Across the EU5 Welcome the Launch of Biosimilars in the RA Market and Anticipate Encouraging or Imposing the Prescription of These Agents to Control the Spending of High-Cost Biologics

View Now